Background
Conventional radiotherapy (RT) using X-rays and γ-rays is used for the treatment of cancers and may be used as primary or in adjuvant settings. Treatment with radiation after breast cancer surgery as well as combined treatment of radiation and chemotherapy is anticipated to improve cancer treatment. Previous studies showed that adding radiation to breast cancer treatment doesn’t just lower a woman’s risk of having a relapse, it also improves survival [
1]. However, radiation is related to potentially serious side effects including ischemic heart disease and pneumonitis, sterility [
2‐
4]. Moreover radiotherapy led to development of radiation-induced adaptive response that contributes recurrence and metastases of breast cancer by upregulating Epidermal growth factor (EGF) receptor (EGFR) and vascular endothelial growth factor (VEGF) receptor (VEGFR) related proteins [
5,
6]. This led to the development of alternative form of RT, popularly known as phototherapy. It is based on the old concept of transfer of light energy or photons to form intermediates, which resulted in the consumption of oxygen. This reaction resulted in the formation of singlet oxygen or reactive oxygen species (ROS). These ROS are extremely toxic and have very short half-life, thus affecting the adjacent cells without affecting the surrounding tissues. Ultraviolet radiation mainly UV-B (290–320 nm) having ~ 4 eV energy will be sufficient to perform chemical reactions either forming DNA photo-adducts or ROS [
7]. UV-B phototherapy is widely used for treating various skin disorders with minimal systemic toxicities and side effects [
8]. Though UV-B has its limitation in reaching to the deeper tissues and organs, but the development of LASER technology along with fiber optic catheters guided by non-invasive imaging techniques e.g., Magnetic resonance imaging, ultrasound imaging makes feasible for the interstitial UV-B phototherapy to act in periphery as well deep tissues and organs harboring the tumor cells. In order to achieve the selective destruction of the target area, tumor specific photosensitizers are either applied locally or intravenously where light can be applied over the accumulated photosensitizers/UV-sensitizers using minimally invasive fiber optic catheters guided by imaging devices. DNA being the intrinsic UV-photosensitizers can form photo-adducts and pyrimidine dimers by the introduction of UV-B radiation, which generally halted the cell cycle progression in the S phase of the cell cycle and induced apoptosis. The dual selectivity of phototherapy due to preferential localization of photosensitizers [
9] or UV sensitizers [
10] only to malignant tissues, and restriction of photo-activation only in the limited zone of irradiation makes it an alternative therapy to pre-existing conventional RT. This phototherapy is considered as more targeted to destroy cancer cells or pathogens and less toxic to surrounding normal tissues than the conventional radiotherapy using ionizing radiation. To investigate the effects of UV-B phototherapy on breast cancer, we constructed a model in which cultivated breast cancer cells were exposed to different doses of UV-B radiation. UV-B radiation induces DNA photoproducts, such as pyrimidine dimers and (6–4) photoproducts [
11,
12]
. Ionizing irradiation produces double- and single-strand DNA breaks. Cells respond to DNA photoproducts and DNA breaks by accumulation of functionally active p53 protein, a key event in response to cellular stress. The signaling pathways that trigger a cell to undergo apoptosis or alter the proliferation in response to UV radiation are not well understood. UV radiation activates p53, cell death receptor, ROS and induces mitochondrial release of cytochrome-
c, leading to apoptosis [
13,
14]. Most of the clinical settings of UV-B used in treatment of skin disorders are principally based on the effect of UV-B on apoptotic effects of the irradiated cells.
RT alone, however, has not yielded ideal clinical outcome and it is often associated with increased production of EGF and VEGF that contributes to radio-resistance [
15] by activating growth factor mediated pathways in squamous and mammary carcinoma cells [
16‐
18]. Radiation exposure activates mitogen activated protein kinase (MAPK) pathway to a level similar to that observed by physiological growth stimulatory, EGF concentrations [
16,
17,
19]. MAPK signaling has also been linked to increased expression of growth factors such as EGF, VEGF and transforming growth factor alpha (TGFα), leading to increased proliferative rate of surviving cells [
20‐
22]. Growth factors such as VEGF and TGFα, in addition to a growth-promoting role
in vitro, may also play an important role in the development of tumors
in vivo due to their abilities in the promotion of angiogenesis. Like RT, UV radiation also activates VEGF signaling involving EGF/PI3K pathway, activates invasion by activating metalloproteinase [
23‐
25]. Collectively, these findings argue that UV-B phototherapy may have a self-limiting effect on its toxicity via increased activity of EGFR and VEGFR and downstream signaling molecules such as the MAPK pathway. Thus, one interesting and promising research direction for improving the treatment of breast cancer could be a molecular-targeted therapy against EGFR and VEGFR in association with UV-B phototherapy.
Several studies demonstrate that the expression of EGF and EGFR is related with breast cancer growth, progression and aggressiveness and its overexpression is an indicative of poor prognosis [
26,
27]. VEGF is closely associated with the promotion of angiogenesis, increment of micro-vessel density and with early relapse in primary breast cancer [
28], yet clinical trials of agents that target either EGF or VEGF signaling pathways alone have been disappointing. Some tumors may not respond well to EGFR inhibitors alone or may develop resistance to EGFR inhibitors. We hypothesized that targeting both the tumor and its vasculature by VEGF- and EGF-receptor (VEGFR, EGFR) blockade would improve breast cancer treatment and provide wider applicability particularly when combined with UV-B phototherapy. To test this hypothesis, we evaluated the feasibility of combining ZD6474, a dual tyrosine kinase inhibitor of VEGFR and EGFR [
29‐
32], with UV-B radiation in breast cancer cell lines MCF-7, MDA-MB-231, MDA-MB-468 and T-47D. This preclinical work was undertaken to serve as a rationale to support the role of ZD6474 in the treatment of skin lesions infiltrated with metastatic breast cancer cells and also for the recurrence breast cancer with UV-B phototherapy, a promising treatment alternative to RT.
Discussion
Locally advanced breast cancer constitutes 30-60% of breast cancer cases and remains a clinical challenge as the majority of patients with this diagnosis develop distant metastases despite appropriate and preexisting radiotherapy and surgery [
33]. Locally advanced breast cancers are often associated with higher expression of growth factors EGF, VEGF that are associated with shorter relapse free survival or over-all survival and aggressiveness of the disease [
34,
35]. Thus, there is a requirement of developing non-toxic, more effective novel therapeutic approach to combat this loco-regional recurrence of breast cancer, particularly for the patients treated prior with RT. These studies were initiated to further understand the role of VEGF with aggressive nature of breast cancer cells
in vitro. MDA-MB-231 and MDA-MB-468 showed higher expression of VEGF and are more aggressive as compared to T-47D and MCF-7, least aggressive of the four cell lines. IC
50 was > 40 J/m
2 in both MDA-MB-468 and MDA-MB-231 cells. IC
50 was < 40 J/m
2 in T-47D and the IC
50 ~100 J/m
2 for MCF-7 irradiated cells (Figure
1). It indicates that the higher levels of VEGF in breast cancer cells
in vitro are more sensitive to phototherapy (UV-B), and the lesser expression of VEGF will help in the normal mammary endothelial cells to escape the UV-B phototherapy, an important factor to consider for the safety of UV-B phototherapy in breast cancer treatment. Previous findings have shown that higher levels of EGF, VEGF and their cognate receptors were found to be the predictor of radio-response as compared to non-responders [
34]. We observed similar findings with UV-B phototherapy. Previously it was also noticed that UV induced DNA damage resulting in cell death is dependent on nuclear excision repair protein (NER) protein [
36]. In order to check the effect of UV-B radiation on nucleotide excision repair (NER) pathway, we have checked the level of XPA and ERCC1 expression (Additional file
2: Figure S2), and found that the sensitivity of UV-B in mediating cell death doesn’t completely depend on the level of NER pathway involved proteins i.e. XPA and ERCC1. Thus, the additional pathway might be involved in UV-B mediated cell death. It was shown that apart from DNA damage induced cell death by UV-B, death receptor pathway, decrease in mitochondrial potential (ΔΨm) and ROS are also involved in cell death [
14,
37,
38]. Moreover, it was earlier reported that the “window “ of operating NER pathway is confined to low doses of UV-B where as at high doses of UV-B, NER involvement is not observed, and the apoptotic mechanism dominates over NER pathway [
39]. To date, the pathways involving UV-B mediated apoptosis is not well elucidated and interestingly we have found a strong correlation of UV-B sensitivity and VEGF expression in breast cancer cells. Considering also the fact that UV-B lead to VEGF overexpression resulting in radio-resistance, it prompted us to investigate the role of anti-VEGF agent in sensitizing UV-B phototherapy mediated apoptosis in breast cancer cells.
RT is effective modality of treatment widely used for treating higher staging or locally advanced breast cancers [
40]. Although widely used, a need remained to improve the cure rate by RT alone. The treatment based on chemotherapeutic agents paclitaxel, doxorubicin to RT in non-operable and recurrent disease, was found to be of good efficacy [
41‐
43]. The cytotoxicity of chemotherapeutic agents, however, is not limited to tumor cells because treatment of tumors with these agents can result in significant normal tissue toxicity. Thus, the current therapeutic challenge is to optimize available non-operative strategies by incorporating new non-cytotoxic agents into current therapeutic regimens of RT. These led to the development of antiangiogenic therapies or molecular targeted therapies (Tyrosine kinase inhibitors) that target specific receptors VEGFR in endothelium cells that forms capillaries and supplies nutrients for hundreds of tumor cells. Hence, targeting of the tumor vasculature should lead to a potentiation of the antitumorigenic effect [
44]. Some recent preclinical studies suggest that the combination of RT and angiogenic blockade enhances the therapeutic potential of ionizing radiation by targeting both tumor cells and tumor vessels [
45,
46]. However, loco-regional recurrence of breast cancer after surgery and post-operative RT occurs around 10-20% and 5-8% respectively [
25]. Thus, phototherapy utilizing the energy of photons in combination with photosensitizers can be used to direct the energy to generate ROS or DNA damage in the tissue specific manner seems to be a promising alternative for treatment of advanced breast cancer patients for whom the RT is limited due to prior therapies. There is a recent development of targeted phototherapy, photosensitizers [
47,
48] that further minimizes the toxicities associated with UV phototherapy. Ionizing radiation enhances both epithelial growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) expression, and similar results were obtained with UV radiation [
23,
49], which are a part of key pathways for tumor progression and radioresistance [
16]. It was also noticed that there was positive correlation between VEGF expression and ZD6474 sensitivity in decreasing cell proliferation as shown in Figure
1C. Thus, it supports the rational of combining UV-B radiation and ZD6474 in treating breast cancer cells. Moreover, it was found that 5-flurouracil, an anti-cancer drug with ionizing radio-sensitization activity, also enhanced the UV-B mediated apoptosis in breast cancer [
50]. Previously it was shown that dual targeting of EGFR and VEGFR in combination with RT enhanced antitumor activity of lung cancer
in vivo as compared to either agent alone [
51]. Considering these previous findings, it is likely that EGFR and VEGFR-TKI ZD6474, when combined with UV-B phototherapy, will improve tumor control and provide wider applicability. The mechanisms by which tumor response to UV-B radiation is enhanced by ZD6474, however, are not currently understood.
In our study using
in vitro breast cancer cells MCF-7 and MDA-MB-468 that closely recapitulates breast cancer with lower and higher VEGF expression respectively, we found that ZD6474 substantially improved radio-response to UV-B in both cell lines. The radio-sensitivity to UV-B was > 2-fold in higher expressed VEGF producing MDA-MB-231 and MDA-MB-468 (Table
1) when treated with 1 μM ZD6474 in combination with UV-B. The mechanism underlying the decrease in cell viability following combination treatment with ZD6474 and UV-B was studied. The photomicrograph of MCF-7 and MDA-MB-468 irradiated with increasing doses of UV-B clearly demonstrated the involvement of apoptosis in decreasing cell viability (Figure
2) with lesser involvement of antiproliferative effects, which was further confirmed from cell counts using trypan blue dye exclusion assays. It was shown earlier that UV radiation induced apoptosis as compared to ionizing radiation that mainly induced cell cycle arrest in osteosarcoma
in vitro[
52]. Moreover the extent of DNA damage, cell type, and genetic alterations determined the cells/tissues response to radiation to undergo either apoptosis or cell cycle arrest. Hence, the elucidation of the mechanism of UV-induced apoptosis in breast cancer will be important to make a rational decision for combining UV-B radiation with chemotherapeutic agents or small inhibitors e.g., TKI. In contrast to UV-B, ZD6474 is more an antiproliferative agent than a cytotoxic agent at its lower concentration (<IC
50). The enhanced activity of ZD6474 in decreasing cell viability may be contributed both due to antiproliferative and apoptotic effects of combination treatment (Figure
2). ZD6474 significantly potentiates the apoptotic activity of UV-B as shown by flow-cytometry (Figure
2). Formation of oligonucleosomes or fragmented DNA, membrane blebbing further confirmed that cell death was due to activation of the apoptotic pathway as shown in Figure
4. Our findings have shown that ZD6474 may improve the therapeutic index for UV-B phototherapy by enhancing tumor-specific cytotoxicity.
Non-cytokine-mediated cellular stress, such as UV or chemical treatment, can initiate apoptosis through mitochondrial release of cytochrome-
c[
13]. There was a significant change in mitochondrial membrane potential (ΔΨm) that is associated with release of cytochrome-
c in cytosol, initiating the apoptotic pathway mediated by mitochondria. There was also change in bax translocation (Figure
3), further implying the involvement of mitochondria in stress signaling pathway induced by UV-B radiation [
53]. It was also found that ZD6474 increased the active form of caspase-7 (effector caspase in MCF-7 as it is deficient in caspase-3) in UV-B irradiated cells. It was confirmed both by catalytic activity of caspase-7 and protein expression observed by western blotting. But the enhanced catalytic activity of ZD6474 induced UV-B irradiated MDA-MB-468 was found to be associated with increased expression of active form of casapse-3 (Figure
4). There was also a slight change in caspase-7 activity (data not shown) in ZD6474 induced UV-B irradiated MDA-MB-468 cells. These eventually led to the formation of apoptosome, a multi-protein complex containing cytochrome-
c, Apaf-1, and pro-caspase-9 and finally activation of effector caspase-3/7 leading to apoptosis [
54].
The molecular mechanism involving the enhanced activity of combination treatment was further investigated by western blotting. There was a decrease in cyclin E (Figure
4) expression following combination treatment as compared to untreated control and exposure to single agents alone, indicating cell cycle arrest at G
1-S or synthetic phase in UV-B irradiated cells. UV-B radiation in presence of ZD6474 induced DNA damage irreparable that ultimately arrested the irradiated cells at synthetic S or G
1-S phase of cell cycle [
55]. There was a decrease in expression of cyclin E in ZD6474 induced UV-B irradiated cells which is in agreement with our prior findings [
56]. The alteration of both cyclin D1 and cyclin E was associated with breast cancer progression, early relapse, poor prognosis and chemo-resistance to various cytotoxic agents [
57‐
59]. There was an increase in expression of p53, and a decrease in anti-apoptotic bcl-2 protein in breast cancer cells treated with combined ZD6474 and UV-B (Figure
4). The increase in p53 expression after cytotoxic insults was obvious, which is in agreement with previous and recent findings [
52,
60]. Previous findings had shown that increase in p53 expression was mainly due to p53 stabilization in irradiated cells as compared non-irradiated cells or cells capable of DNA repair. It was also shown that there was more increased expression of p53 in UV-B irradiated cells as compared to X-ray irradiated cells, eventually leading to more apoptosis in the former irradiated cells. Though p53 level was unchanged in ZD6474 treated cells, but its addition in the treatment strategy of UV-B irradiated cells increased the cytotoxicity nature of the cells that lead to further insults in DNA damages as evident in cell viability and flow-cytometric assays which were in consistent with higher expression of p53 in combination treatment in wild type p53 MCF-7 cell line (Figure
4), and no such change was associated with mutant p53 bearing MDA-MB-468. Previous findings had shown that UV induced apoptosis via direct p53-E2F1-Bcl-2 pathway by downregulating Bcl-2 where as it can also induced apoptosis in p53 independent manner via direct effect of Bcl-2 regulation by pyrimidine dimers [
61]. Thus, Bcl-2 might play an important role in UV-B induced apoptosis. So, we checked the Bcl-2 expression in combined therapy, and noticed that Bcl-2 was downregulated by UV-B radiation in cell lines expressing wild type p53 (MCF-7) and its mutant form (MDA-MB-468), indicating that UV-B induced apoptosis acts through both p53 dependent and independent pathways which is in agreement with prior findings [
61,
62].
Cell migration and invasion are crucial steps in the physiopathology of development of cancer and metastasis [
63,
64]. ZD6474 inhibited motility of breast cancer cells (Figure
5) that was further decreased when ZD6474 is combined with UV-B. It was found that 48 h was required to fill the scratch in MCF-7 as compared to 24 h in MDA-MB-468, which is in agreement with previous findings that MDA-MB-468 is more aggressive of the two due to higher content of VEGF (chemotactic growth factors) in the former. We found that ZD6474 decreased VEGF expression probably by downregulating PI3K pathway [
65] that contributes to downregulation of VEGF transcription (Figure
5E, and
5F). Though not significant, but an increased in VEGF level was observed in both cell lines when treated with UV-B radiation. It might be due to the fact that the cytotoxic effects induced by UV-B dose that was used in the experiment inhibited VEGF expression probably. There are reports, which suggest that UV radiation is an inducer of VEGF [
23,
66]. Thus the addition of ZD6474 to UV-B radiation might be beneficial in inhibiting its proangiogenic related activities.
The decreased motility observed in these cells may have an effect on cytoskeletal and cell adhesion molecules induced by ZD6474. Motility depends on an ordered series of events that require cell polarization, membrane extension into a lamellipodium, filipodium, attachment of the leading edge to the substratum, traction by stress fibers formed from the leading edge, and release of the lagging end of the cell. ZD6474 decreased cellular lamellipodia and filopodia extrusions and resulted in an almost complete loss of these projections in combination treatment (Figure
6A, and
6B). ZD6474 also increased E-cadherin expression in both cell lines (Figure
4E). Thus, ZD6474 stabilized cytoskeletal structure and inhibited invasion and migration of cancer cells. This is consistent with earlier studies demonstrating that intermediate levels of adherence are needed for optimal migration and that increasing or decreasing adherence actually decreases the rate of cell migration [
67,
68]. Loss of actin organization is characteristic of many tumor cells. Our results suggest that ZD6474 stabilized stress actin filaments, characteristics of normal differentiated cells. In case of UV-B irradiated cells, the change was not significant but the combined treatment with ZD6474 and UV-B led to disorganized actin filaments due to increased apoptosis [
69].
Materials and methods
Cell lines
Human breast cancer cell lines MCF-7, MDA-MB-231 and MDA-MB-468 were cultured in Dulbecco’s Modified Eagle’s Medium: Nutrient Mixture F-12 (Ham) (D-MEM/F-12) with 15 mM HEPES buffer, L-glutamine, pyridoxine hydrochloride, supplemented with 1.2 g Sodium bicarbonate (Invitrogen Corporation, CA), antibiotics (10,000 U/L penicillin and 10 mg/L streptomycin) (Himedia, Mumbai, Maharashtra India) and 10% fetal bovine serum (FBS) (Invitrogen, Grand Island, NY, USA). T-47D and ZR-751 cells were grown in RPMI-1640, supplemented with 10% FBS. Human Mammary Epithelial Cells (HMEpC) (Cell Applications, Inc., San Diego, CA, USA) and were grown as per as manufacturer instructions. Cells were incubated at 37°C in a 5% CO2 and 95% humidified incubator.
Reagents
Stock solutions of 20 mM ZD6474 (AstraZeneca Pharmaceuticals, Macclesfield, United Kingdom) were dissolved in DMSO (Sigma-Aldrich, St. Louis, MO, USA), stored at −20°C, and diluted in fresh medium just before use. For Western blot analysis, the following antibodies were used: rabbit monoclonal anti-PARP, anti-E-cadherin, mouse monoclonal anti-cyclin E, anti-caspase-3, (Cell Signaling Technology, Beverly, MA, USA), mouse monoclonal anti-caspase-7 (BD Pharmingen, Franklin Lakes, NJ, USA), mouse monoclonal anti-β-actin (Sigma-Aldrich), mouse polyclonal anti-bcl-2, anti-bax, anti-p53, horseradish peroxidase-conjugated goat anti-rabbit IgG and goat anti-mouse IgG, alkaline phosphatase-conjugated goat anti-rabbit IgG and goat anti-mouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Chemiluminescent peroxidase substrate, BCIP/NBT, Propidium iodide (PI), 4′,6-diamidino-2-phenylindole (DAPI) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), acetyl-Asp-Glu-Val-Asp p-nitroanilide (Ac-DEVD-pNA), Gelatin A and Gelatin B (Sigma-Aldrich), and Fluorescein phalloidin (Molecular Probes™, Invitrogen Corporation, Eugene, Oregon) , were purchased from the indicated company. Stock solutions of PI and DAPI were prepared by dissolving 1 mg of each compound in 1 ml PBS and MTT in incomplete medium. The solution was protected from light, stored at 4°C, and used within 1 month. Stock concentrations of 10 mg/ml RNase A dissolved in water and 20 mM Ac-DEVD-pNA (Sigma-Aldrich) dissolved in DMSO were prepared and kept at −20°C.
UV-B irradiation
For UV-B irradiation, the medium was removed from cells grown in cell culture plates or in 96-well tissue before UV exposure. Cells were exposed to UV-B using a UV cross-linker (Agilent Technologies, Inc., Stratagene, Santa Clara, CA, USA) equipped with 598 W tubes which emit most of their energy within the UV-B range (290–320 nm) with an emission peak at 312 nm [
70]. Control cells were treated similarly by the same protocol, except for radiation. After irradiation, cells were re-incubated in culture medium with or without ZD6474.
Evaluation of cytotoxicity of ZD6474 and/or UV-B irradiation
Cells were harvested in the logarithmic phase of growth; cell suspensions were dispensed (200 μl) into 96-well tissue culture plates at an optimized concentration of 1 × 104 cells/well in complete medium. 24 h after seeding, cells were irradiated with UV-B (1–200 J/m2) after the removal of the medium, and then reincubated for 48 h in the medium with different concentration of ZD6474 along with control treatment (0.1% DMSO. Cell viability was measured by MTT dye reduction assay at 540 nm. The dose-effect curves were analyzed using Prism software (GraphPad Prism 5.0, San Diego, CA, USA). For all subsequent experiments 1 μM ZD6474 and 25 J/m2 UV-B dose was selected, until otherwise mentioned.
Apoptosis measurement by flow-cytometry
To study the effect of combination treatment of ZD6474 and UV-B cells were irradiated with 25 J/m2 UV-B, followed by treatment with 1 μM ZD6474 for 48 h after seeding in 60-mm tissue culture plates. After treatment, both attached and floating cells were collected and washed in phosphate-buffered saline (PBS) and incubated in 70% ethanol, kept at −20°C overnight for fixation. Cells were centrifuged, washed and then incubated with PI solution (40 μg/ml PI, 100 μg/ml RNase A in PBS) at 37°C for 1 h. Apoptotic cells were determined by their hypochromic sub-diploid staining profiles. The distribution of cells in the different cell-cycle phases was analyzed from the DNA histogram using Becton-Dickinson FACSCalibur flow-cytometer and CellQuest software.
Measurement of mitochondrial membrane potential (ΔΨm)
To measure mitochondrial transmembrane potential (ΔΨm), rhodamine 123 (Rh-123) were used [
71]. MCF-7 and MDA-MB-468 cells were treated with ZD6474 and/or UV-B radiation for 12 h. After that cell were washed with PBS, and were stained with Rh-123 at the final concentration of 5 μg/ml for 30 min at 37°C. Samples stained with Rh-123 were subjected to flow-cytometry (Becton Dickinson FACS Calibur flow-cytometer) (BD, San Jose, CA, USA). The emission wavelength was detected through the FL1 channel. Data were acquired and analyzed with CellQuest software.
Preparation of cytosolic and mitochondrial extracts
Cytosolic and mitochondrial extracts were prepared as described previously [
72]. MCF-7 and MDA-MB-468 cells were seeded in 90-mm cell culture plates for 1 day, and treated as indicated. Cells were then harvested and washed in PBS. After spinning down, cells were resuspended in 100 μl of HED buffer (10 mM HEPES pH 7.9, 10 mM Kcl, 0.1 mM EDTA pH 8, 1.0 mM dithiothreitol (DTT)) containing 0.4% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride (PMSF), protease cocktail inhibitor), After incubation on ice for 20–30 min, cell suspensions were vortexed for 10 sec for cell lysis, followed by centrifugation at 5000 rpm for 5 min at 4°C. Cytosolic protein (supernatant) was collected and further centrifuged at 10000 rpm, 30 min to remove crude membranes and to obtain a clear cytosolic fraction free of membrane debris, and stored at −70°C. Mitochondrial extracts (cell pellet) were then washed with mitochondrial extraction buffer (10 mM HEPES pH 7.4, 200 mM mannitol, 70 mM sucrose, 1 mM EGTA or EDTA pH 8, 1 mM DTT, 1 mM PMSF, protease cocktail inhibitor) to remove any traces of cytosolic extract, and finally lysed with 50 μl of mitochondrial extraction buffer on ice for 60 min with intermittent vortexing. Mitochondrial protein was collected after centrifuging at 15,000 rpm for 30 min at 4°C, aliquot and stored at −70°C.
Western blot analysis of growth regulatory proteins and apoptosis proteins
Cells were treated with ZD6474 and/or UV-B and then the cells were scraped and lysed in Nonidet P-40 lysis buffer (50 mM Tris HCl pH 8.0, 137 mM sodium chloride, 10% glycerol, 1% Nonidet P-40, 50 mM sodium fluoride, 10 mM EDTA) containing 1 mM sodium vanadate, 1 mM phenylmethylsulfonyl fluoride, and protease cocktail inhibitor for obtaining total cell extracts. Equal amount of cell extracts were separated on a 10% sodium dodecyl sulfate-polyacrylamide electrophoretic gel (SDS-PAGE) and transferred to nitrocellulose membranes, which were blocked with 2% BSA and probed with the appropriate antibodies and secondary antibodies. Membranes were then developed using enhanced chemiluminescence or alkaline phosphatase-based colorimetric methods.
Caspase-3 and caspase-7 activity assays
Caspase-3 and caspase-7 activity was determined by measuring the absorbance at 405 nm after cleavage of synthetic substrate acetyl-Asp-Glu-Val-Asp p-nitroanilide (Ac-DEVD-pNA) as described previously [
73] with some modifications [
56]. Cells were treated with ZD6474 and/or UV-B radiation for 48 h, and lysed with buffer (50 mM HEPES, pH 7.4, 5 mM CHAPS, 5 mM DTT, 1 mM PMSF, 20 μg/ml leupeptin), followed by centrifugation at 20,000 g for 15 min at 4°C. The lysates (50 μl) were incubated in 200 μM solution of (Ac-DEVD-pNA) in a reaction buffer (20 mM HEPES, pH 7.4, 2 mM EDTA, 0.1% CHAPS, 5 mM DTT) at 37°C. The reaction was monitored for 1–3 h, and the absorbance was recorded at 405 nm. If the signal was low, the reaction can be monitored for 12–24 h. The formation of pNA was calculated as the difference in the absorbance at 405 nm unit time (min) per unit volume (ml) of sample. The relative levels of pNA formation were normalized against the protein concentration (mg/ml) of each extract to obtain specific activity (μ moles pNA/min/mg).
Where,
ϵ = 10.5
v = volume of sample in ml
t = reaction time in minutes
c = concentration of sample in mg/ml
In vitro wounding (scratch) assay
To test the invasive behavior of treated cells, 1 × 10
5 cells were plated in 6-well tissue culture plates and grown for 24 h to obtain a confluent monolayer and migration was studied by
in vitro wounding (scratch) assay [
74] with slight modifications. The monolayer was scraped (wounded) in a straight line to create a “wound (scratch)” with a p200 pipette tip. The debris were removed and the edge of the wound (scratch) was made smooth by washing the cells once with 1 ml of the growth medium and then replaced with 3 ml of complete media along with ZD6474 and/or UV-B. Cells were observed 48 h post-treatment. Cells invading the wound (scratch) line were observed under an inverted phase-contrast microscope (Leica Microsystems, Wetzlar, Hesse, Germany). The distances between one sides of the scratch with another were measured after the indicated time intervals using the Leica Qwin software. The distance of each wound (scratch) closure was the measure of wound healing. P-values of wound size were calculated using un-paired t-test between the same treatment group, prior and post treatment. Each experiment was performed three times with triplicate samples.
Scanning electron microscopy (SEM)
Cells were grown in cover slip at a density of 10,000 cells per cover slip. Cells were treated with ZD6474 and/or UV-B radiation for 1 day. After that Cells were fixed with 3.7% Paraformaldehyde (Merck, Mumbai, Mahrashtra, India) for 30 min, followed by serial dehydration in alcohol (50%, 70%, 75%, 90% , 95% and 100% for 5 min at each step) and finally subjected in 100 μl 1,1,1,3,3,3-Hexamethyldisilazane (HMDS) for critical point drying. Samples were then air dried at room temperature and mounted on stub. Next, they were placed in vacuum chamber of SEM gold coating apparatus and gold was coated at 2.5 kV, 20–25 mA for 120 s. The morphogram (surface features) of the MCF-7 and MDA-MB-468 cells were then observed using a JEOL JSM-5800 Scanning Microscope (Zeol, Peabody, MA, USA) using 20 kV acceleration voltages.
Immunofluorescence studies
MCF-7 and MDA-MB-468 cells were plated on coverslips in DMEM/F-12 complete medium. After 1 day, cells were treated with 1 μM ZD6474 and/or 25 J/m2 UV-B for 1 day. Cells were fixed in 3.7% paraformaldehyde, and permeabilized with 0.1% Triton-X-100 and then blocked in 2% BSA, and stained with FITC phalloidin to visualize F-actin (Life Technologies, Grand Island, NY, USA), counterstained with DAPI as per manufacturer’s instructions. Cells were analyzed by confocal laser scanning microscopy (CLSM) (Olympus FluoView FV1000, Version 1.7.1.0) (Olympus, Tokyo, Japan), using the appropriate wavelength. Images were captured and digitized using FLUOVIEW 1000 (Version 1.2.4.0) imaging software.
VEGF quantification
Breast cancer cells were treated with ZD6474 and/or UV-B and incubated in incomplete medium for 48 h. The conditioned medium (CM) was collected and kept at −70°C for studying secretory proteins (VEGF, MMPs). The concentration of VEGF in the serum-free CM obtained from cultured cells was measured using commercially available sandwich ELISA kits (R&D Systems Inc., Minneapolis, MN, USA) and according to manufacturers’ instructions and the level of VEGF was reported in ng/ml which is normalized to the number of cells.
Zymography
Activity of matrix metalloprotease-2 (MMP-2) and matrix metalloprotease-9 (MMP-9) was assessed by gelatin Zymography [
75]. Briefly, to prepare serum-free conditioned media (CM), cells were allowed to grow to subconfluence in 35-mm tissue culture dishes in DMEM/F-12 containing 10% FBS. After several washes with serum-free medium, the medium was replaced with DMEM/F-12 containing ZD6474 after treatment with UV-B, and the cultures were incubated for an additional 48 h. The conditioned media were collected and applied to SDS-polyacrylamide gels (7.5% w/v) copolymerized with gelatin (0.1% w/v) and washed twice in renaturation buffer (2.5% Triton-X-100) equilibrated in developing buffer (50 mM Tris-cl pH 8.3, 0.2 M Nacl, 5 mM Cacl
2, 0.02% Brij-35) for initial 30 min at 37°C, followed by incubation in developing buffer at 37°C for 24 h. Enzyme-digested regions were quantified by QuantityOne® (Version 4.2.1) after data acquisition using GS-800™ Calibrated Densitometer (Bio-Rad, Hercules, CA, USA).
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SS designed, carried out the experiments and also prepared the draft of the manuscript. SR and AK helped in cell culture, preparation of slides for microscopy, and also correcting the manuscript. MM approved the experimental design, assisting the experiments and help in preparing the final draft of the manuscript. All authors read and approved the final manuscript.